Therapeutics for multiple sclerosis symptoms

Mount Sinai Journal of Medicine

Volumn 78, Issue 2, 2011, Pages 176-191

  Ben Zacharia, Aliza Bitton ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

multiple sclerosis; quality of life; rehabilitation; symptoms management

Indexed keywords

AMANTADINE; AMPHETAMINE; AMPHETAMINE PLUS DEXAMPHETAMINE; AMPYRA; ARMODAFINIL; BACLOFEN; BETHANECHOL; BISACODYL; BOTULINUM TOXIN A; CARBAMAZEPINE; CLONAZEPAM; DALFAMPRIDINE; DANTROLENE; DARIFENACIN; DIAZEPAM; ETIRACETAM; FLUOXETINE; GABAPENTIN; METHYLPHENIDATE; MODAFINIL; OXCARBAZEPINE; OXYBUTYNIN; POTASSIUM CHANNEL BLOCKING AGENT; PREGABALIN; PROPRANOLOL; SOLIFENACIN; TAMSULOSIN; TIZANIDINE; TOLTERODINE; TOPIRAMATE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AGITATION; ANGINA PECTORIS; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATAXIA; BEDTIME DOSAGE; BEHAVIOR MODIFICATION; BLADDER DYSFUNCTION; BLOATING; BLOOD DYSCRASIA; BLOOD PRESSURE; BLURRED VISION; BRAIN DEPTH STIMULATION; CEREBELLAR ATAXIA; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFUSION; CONSERVATIVE TREATMENT; CONSTIPATION; COUNSELING; DEPRESSION; DEVICE THERAPY; DIAPHORESIS; DIARRHEA; DIPLOPIA; DIZZINESS; DORSAL RHIZOTOMY; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DYSURIA; EDEMA; ENERGY CONSERVATION; FATIGUE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE; HUMAN; HYPONATREMIA; INSOMNIA; IRRITABILITY; LETHARGY; LIBIDO; LIFESTYLE MODIFICATION; MARITAL THERAPY; MENTAL INSTABILITY; MULTIPLE SCLEROSIS; NAUSEA; NERVOUSNESS; NEUROGENIC BLADDER; NEUROGENIC BOWEL; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; OCCUPATIONAL THERAPY; ORTHOSTATIC HYPOTENSION; PATIENT COUNSELING; PERIPHERAL EDEMA; PHYSIOTHERAPY; PSEUDOBULBAR AFFECT; PSYCHOTHERAPY; QT PROLONGATION; QUALITY OF LIFE; REHABILITATION CARE; SALIVATION; SEIZURE; SEX THERAPY; SEXUAL DYSFUNCTION; SIDE EFFECT; SMOKING CESSATION; SOCIAL SUPPORT; SOMNOLENCE; SPASTICITY; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; STRETCHING EXERCISE; TACHYCARDIA; TENDON TRANSFER; TOXIC HEPATITIS; TREMOR; URINE RETENTION; VISION; VISUAL DISORDER; WALKING AID; WALKING DIFFICULTY; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ATAXIA; COMBINED MODALITY THERAPY; DEPRESSION; GAIT DISORDERS, NEUROLOGIC; HUMANS; MENTAL COMPETENCY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; PATIENT CARE MANAGEMENT; PATIENT SELECTION; PHARMACEUTICAL PREPARATIONS; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SOCIAL ISOLATION; SOCIAL SUPPORT; URINARY RETENTION;

EID: 79953019065     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20245     Document Type: Article

References (46)

1. Cohen B., Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis. Neurology 2008; 71: S14-S20.
2. Bergamaschi R, Romani A, Versino M, et al,. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 1997; 12: 247-251. (Pubitemid 28023053)
3. Krupp L., Fatigue in Multiple Sclerosis: A Guide to Diagnosis and Management. New York, NY: Demos; 2004.
4. Kos D, Kerckhofs E, Nagels G, et al,. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair 2008; 22: 91-100. (Pubitemid 350223141)
5. Mills RJ, Young CA, Pallant JF, et al,. Development of a patient reported outcome scale for fatigue in multiple sclerosis: the Neurological Fatigue Index (NFI-MS). Health Qual Life Outcomes 2010; 8: 22.
6. Goodman AD, Cohen JA, Cross A, et al,. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007; 13: 357-368. (Pubitemid 46705997)
7. Goodman AD, Brown TR, Cohen JA, et al,. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008; 71: 1130-1131.
8. Goodman AD, Brown TR, Krupp LB, et al,. Sustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trial. Lancet 2009; 373: 732-738.
9. Thompson AJ., Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 2010; 9: 1182-1199.
10. Boissy AR, Cohen JA., Multiple sclerosis symptom management. Exp Rev Neurother 2007; 7: 1213-1222. (Pubitemid 47451027)
11. Rizzo MA, Hadjimichael OC, Preiningerova J, et al,. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589-595. (Pubitemid 39207235)
12. Giovannelli M, Borriello G, Castri P, et al,. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007; 21: 331-337. (Pubitemid 47064552)
13. Baba MY, Osborne M, Wszolek ZK, et al,. Treatment of spasticity with botulinum toxin. Ortop Traumatol Rehabil 2004; 6: 665-672.
14. Ben-Zacharia A, Lublin F., Palliative care in patients with multiple sclerosis. Neurol Clin 2001; 19: 801-828.
15. Foster HE Jr,. Bladder symptoms and multiple sclerosis. MSQR Multiple Sclerosis Quarterly Reprint 2002; 21: 5-8.
16. Kalsi V, Gonzales G, Popat R, et al,. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007; 62: 452-457. (Pubitemid 350308769)
17. Mehnert U, Birzele J, Reuter K, et al,. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol 2010; 184: 1011-1016.
18. Fletcher SG, Castro-Borrero W, Remington G, et al,. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol 2009; 6: 96-107.
19. Dasgupta R, Wiseman OJ, Kanabar G, et al,. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004; 171: 1189-1193. (Pubitemid 38327555)
20. Billups KL, Berman L, Berman J, et al,. A new non-pharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther 2001; 27: 435-441. (Pubitemid 32802776)
21. Minden SL, Orav J, Reich P., Depression in multiple sclerosis. Gen Hosp Psychiatry 1987; 9: 426-434. (Pubitemid 17165071)
22. Sadovnick AD, Remick RA, Allen J, et al,. Depression and multiple sclerosis. Neurology 1996; 46: 628-632. (Pubitemid 26099623)
23. Schiffer RB, Caine ED, Bamford KA, et al,. Depressive episodes in patient with multiple sclerosis. Am J Psychiatry 1983; 140: 1498-1500. (Pubitemid 13017392)
24. Feinstein A., An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002; 59: 674-678.
25. Haussleiter IS, Brüne M, Juckel G., Psychopathology in MS: diagnosis, prevalence and treatment. Ther Adv Neurol Disord 2009; 2: 13-29.
26. Mohr DC, Classen C, Barrera M Jr,. The relationship between social support, depression and treatment for depression in people with multiple sclerosis. Psychol Med 2004; 34: 533-541. (Pubitemid 38559154)
27. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005; 11: 328-337.
28. Dark FL, McGrath JJ, Ron MA., Pathological laughing and crying. Aust N Z J Psychiatry 1996; 30: 472-479. (Pubitemid 26312992)
29. Wilson SAK., Some problems in neurology. II. Pathological laughing and crying. J Neurol Psychopathol 1924; 4: 299-333.
30. Panitch HS, Thisted RA, Smith RA, et al,; for the Pseudobulbar Affect in Multiple Sclerosis Study Group. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006; 59: 780-787. (Pubitemid 43673155)
31. Benedict RH, Bobholz JH., Multiple sclerosis. Semin Neurol 2007; 27: 78-85. (Pubitemid 46239042)
32. Rao S., Cognitive function in patients with multiple sclerosis: impairment and treatment. Int J MS Care 2004; 6: 9-22.
33. Honarmand K, Akbar N, Kou N, et al,. Predicting employment status in multiple sclerosis patients: the utility of the MS functional composite. J Neurol 2010; doi:10.1007/s00415-010-5736-8.
34. Christodoulou C, MacAllister WS, McLinskey NA, et al,. Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? CNS Drugs 2008; 22: 87-97.
35. Krupp L., Improving memory in patients with multiple sclerosis: AIMS study. Paper presented at: American Academy of Neurology Annual Meeting; April 10-17, 2010; Toronto, Canada. Abstract S21.004.
36. Lovera JF, Frohman E, Brown TR, et al,. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010; 16: 715-723.
37. Costello K, Halper J, Harris C., Nursing Practice in Multiple Sclerosis: A Core Curriculum. New York, NY: Demos; 2003.
38. Markowitz C., Symptomatic therapy of multiple sclerosis. Continuum Online, American Academy of Neurology 2010; 16 in press.
39. Tullman M., Symptomatic therapy in MS. Continuum Online, American Academy of Neurology 2004; 10: 142-172.
40. Penner I, Calabrese P., Managing fatigue: clinical correlates, assessment procedures and therapeutic strategies. Int MS J 2010; 17: 28-34.
41. Solaro C, Uccelli MM., Pharmacological management of pain in patients with multiple sclerosis. Drugs 2010; 70: 1245-1254.
42. Starkman JS, Dmochowski RR., Management of overactive bladder with transdermal oxybutynin. Rev Urol 2006; 8: 93-103.
43. Cetin K, Johnson KL, Ehde DM, et al,. Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample. Mult Scler 2007; 13: 1046-1053. (Pubitemid 351541441)
44. Schwid SR., Symptomatic management of multiple sclerosis. Continuum Online, American Academy of Neurology 2007; 13: 181-197. (Pubitemid 47549198)
45. Scott TF, Nussbaum P, McConnell H, et al,. Measurement of treatment response to sertraline in depressed MS patients using the Carroll Scale. Neurol Res 1995; 17: 421-422.
46. Pollman W, Feneberg W., Current management of pain associated with multiple sclerosis. CNS Drugs 2008; 22: 291-324. (Pubitemid 351367440)